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• The aqueous solubility of KYNA was increased by encapsulation with β-CDNS2. 41 
• The molar ratio of CDI to β-CD affected the solubilization efficiency of nanosponges. 42 
• Higher antioxidant activity of KYNA loaded NS was achieved compared to plain KYNA. 43 
• Cell viability study showed that NS was nontoxic to SHSY-5Y human neuroblastoma cell 44 
lines. 45 
• The particle size and zeta potential of KYNA loaded NS and blank NS remained 46 















Kynurenic acid demonstrates antioxidant, neuroprotective and free radical scavenging 60 
properties. However, low aqueous solubility of kynurenic acid limits its therapeutic activity. In 61 
the present study, cyclodextrin nanosponges were used to improve the solubility and therapeutic 62 
activity of kynurenic acid. The formation of kynurenic acid loaded nanosponge was confirmed 63 
by different characterization techniques. The solubility of kynurenic acid was significantly 64 
increased with nanosponge (111.1 µg/ml) compared to free kynurenic acid (16.4 µg/ml) and β-65 
cyclodextrin (28.6 µg/ml). High drug loading (19.06 %) and encapsulation efficiency (95.31 %) 66 
were achieved with NS. The particle size and zeta potential of kynurenic acid loaded nanosponge 67 
was around 255.8 nm and -23 mV respectively. Moreover, higher solubilization of kynurenic 68 
acid loaded nanosponge produced better antioxidant activity compared to free kynurenic acid. 69 
The kynurenic acid loaded nanosponge and blank nanosponge were found nontoxic in the 70 
cytotoxicity assay. Thus, these studies demonstrated that nanosponges can be used as a carrier 71 
for the delivery of kynurenic acid.  72 
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1. Introduction  81 
Kynurenic acid (4-Hydroxyquinoline-2-carboxylic acid; KYNA; Fig. 1A) is an endogenous 82 
substance that is formed from tryptophan via kynurenine metabolic pathway. However, KYNA is 83 
also present in dietary food products such as broccoli, potato, and spices (Turski, Turska, Kocki, 84 
Turski, & Paluszkiewicz, 2015; Turski, Turska, Zgrajka, Kuc, & Turski, 2009). The kynurenine 85 
metabolic pathway endogenously metabolizes tryptophan into KYNA, 3-hydroxykynurenine (3-86 
HK) and quinolinic acid (QUIN) by kynurenine aminotransferase, kynurenine 3-87 
monooxygenase, and kynureninase enzymes, respectively. The 3-HK is a potent free radical 88 
generator and QUIN acts as N-methyl-D-aspartate (NMDA) receptor agonist. However, KYNA 89 
is an ionotropic glutamate and alpha 7-nicotinic receptor antagonist (Vécsei, Szalárdy, Fülöp, & 90 
Toldi, 2013). 91 
KYNA is an excitatory amino acid antagonist possessing neuroprotective properties. The 92 
neuroprotective effect of KYNA was demonstrated by László and beal (László & Beal, 1991). 93 
Carpenedo and co-workers showed the antagonistic activity of KYNA on glutamate receptors 94 
(Carpenedo et al., 2001). Several researchers have demonstrated the antioxidant and free radical 95 
scavenging properties of KYNA. KYNA is formed inside the central nervous system (CNS) and 96 
it is reported that KYNA is also present in human blood and peripheral organs. The decreased 97 
concentration of KYNA in the CNS is associated with several neurological disorders such as 98 
Parkinson’s disease, multiple sclerosis and Huntington’s disease (Schwarcz, Bruno, Muchowski, 99 
& Wu, 2013; Stone & Connick, 1985). However, low aqueous solubility and limited blood-brain 100 
barrier (BBB) permeability limits its therapeutic application (Hornok et al., 2012; Varga et al., 101 
2016). Moreover, kynurenic acid itself has the ability to cross the blood-brain barrier (BBB) to a 102 
limited extent and accumulates in the brain on systemic administration (Stone, 2001). Moroni et 103 
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al. demonstrated that the concentration of KYNA in the mammalian brain is around 10 to 150 104 
nM (Moroni, Russi, Lombardi, Beni, & Carlh, 1988). Several researchers have demonstrated the 105 
effect of KYNA upon systemic administration and its permeation across BBB. Varga et al. 106 
prepared KYNA loaded core-shell nanoparticles of bovine serum albumin (BSA) and 107 
demonstrated that peripheral administration of KYNA loaded BSA nanoparticles are sufficient 108 
enough to produce electrophysiological effects within the central nervous system (Varga et al., 109 
2016). Hornok and co-workers prepared KYNA loaded micelles to demonstrate the 110 
pharmacological activity of KYNA on systemic administration (Hornok et al., 2012).  Moreover, 111 
López et al. earlier demonstrated the synthesis of KYNA loaded silica nanoparticles to improve 112 
the solubilization of KYNA (López, Ortiz, Gómez, la Cruz, Verónica Pérez-de Carrillo-Mora, & 113 
Novaro, 2014). Different ester derivatives of KYNA were also prepared to improve its solubility 114 
and permeability (Dalpiaz et al., 2005).  115 
Cyclodextrin-based delivery systems provide a promising platform to increase drug solubility, 116 
stability, and enhance the drug release profile. The inclusion complex of poorly water-soluble 117 
drugs with α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin is widely reported (A. Singh, 118 
Worku, & Mooter, 2011; Woldum, Larsen, & Madsen, 2008). However, there are certain 119 
drawbacks of native cyclodextrins such as small cavity size of α-cyclodextrin and γ-cyclodextrin 120 
is expensive. β-cyclodextrin is most commonly used in the drug delivery application 121 
nevertheless, β-cyclodextrin exhibits low aqueous solubility and nephrotoxicity (Challa, Ahuja, 122 
Ali, & Khar, 2006).  123 
Several efforts have been made to overcome drawbacks associated with native cyclodextrins 124 
and, to improve their performance, different types of cyclodextrin nanosponges were prepared 125 
earlier. The nanosponges (NSs) are 3-dimensional hyper crosslinked polymer of native 126 
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cyclodextrins prepared with a variety of crosslinking agents such as 1,1’-carbonyldiimidazole 127 
(CDI), pyromellitic dianhydride (PMDA), and diphenyl carbonate (DPC) (Trotta, Dianzani, 128 
Caldera, Mognetti, & Cavalli, 2014; Venuti et al., 2017). Moreover, CDI based nanosponges are 129 
more stable at acidic and alkaline pH and comparatively low toxic to their other counterparts 130 
(Trotta, Zanetti, & Cavalli, 2012). Many researchers have also prepared modified nanosponges 131 
such as ionic β-cyclodextrin polymers (Berto et al., 2007) and glutathione responsive 132 
nanosponges (Trotta et al., 2016). Nanosponges have been utilized for a variety of applications 133 
such as enhancement of aqueous solubility and stability of nutraceuticals (Ansari, Vavia, Trotta, 134 
& Cavalli, 2011; Darandale & Vavia, 2013), encapsulation of proteins (Wajs, Caldera, Trotta, & 135 
Fragoso, 2013) and immobilization of enzymes (Di Nardo et al., 2009). It is also reported that 136 
cyclodextrins based nanocarriers facilitate the permeation of drug molecules across BBB on 137 
systemic administration (Shityakov et al., 2016). Furthermore, Cyclodextrin based NSs can be 138 
administered via several routes depending on the applications (Swaminathan et al., 2010; Torne, 139 
Darandale, Vavia, Trotta, & Cavalli, 2013).  140 
In the present work, we demonstrated the synthesis and characterization of KYNA loaded 141 
cyclodextrin nanosponges. The enhancement in aqueous solubility, antioxidant activity, and in-142 
vitro cell toxicity were also studied.  143 
2. Materials and Method 144 
2.1 Materials  145 
The β-cyclodextrin was a kind gift from Roquette Italia (Cassano Spinola, Italy). Kynurenic 146 
acid, N,N’-carbonyldiimidazole, Thiobarbituric (TBA) acid and 2,2-diphenyl-1-picrylhydrazyl 147 
(DPPH) were purchased from Sigma-Aldrich (Milan, Italy). Cell culture reagents were 148 
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purchased from Gibco/Invitrogen (Life Technologies, Paisley, UK). All other chemicals and 149 
reagents used were of analytical grade unless otherwise specified.  150 
2.2 Methods  151 
2.2.1 Synthesis of β-cyclodextrin nanosponge (β-CDNS) 152 
N,N’-carbonyldiimidazole (CDI) was used as a crosslinker to prepare β-cyclodextrin 153 
nanosponge as reported earlier by our group (Trotta et al., 2012). Briefly, β-cyclodextrin (β-CD) 154 
was dissolved in N,N-dimethylformamide (DMF) and CDI was added in a different molar ratio 155 
of 1:2, 1:4 and 1:6 resulting in the formation of three-different types of nanosponges. The 156 
reaction was carried out at 90 ℃ on a magnetic stirrer for 3 hours   that, it was i cubated 157 
overnight for further crosslinking. The solid monolithic mass of nanosponge was crushed and 158 
washed several times with water to remove unreacted components. The nanosponge was purified 159 
by Soxhlet extraction with ethanol (24 hours), air dried and stored in a desiccator at room 160 
temperature for further use. The nanosponges prepared with CDI were abbreviated as β-CDNS1, 161 
β-CDNS2, and, β-CDNS3 respectively.  162 
The quantities of chemicals used in the synthesis of three-different types of nanosponges are 163 
listed in table 1.  164 
Table 1.  165 
Samples 
Cyclodextrin (β-CD) CDI DMF β-CD:CDI 
Molar Ratio (g) (mmol) (g) (mmol) (ml) 
β-CDNS1 5 4.405 1.426 8.794 30 2 
β-CDNS2 5 4.405 2.852 17.588 30 4 




2.2.2 Determination of swelling degree 167 
All the nanosponges were dried overnight and known amounts of different nanosponges were 168 
placed in water. The swollen nanosponges were removed and excess of water was removed by 169 
blotting on filter paper. The weight of nanosponges was recorded and the above procedure was 170 
followed until a constant weight was achieved. 171 
The following equation was used to calculate % swelling degree. 172 
% Swelling Degree =
Weight in the swollen state − Weight in the dry state
Weight in the dry state
 x 100 
2.2.3 Solubilization efficiency of nanosponges  173 
The aqueous solubility of KYNA alone, with β-CD and with nanosponges (β-CDNS1 to β-174 
CDNS3) was studied. An excess quantity of KYNA was suspended in water (2 ml) and a fixed 175 
quantity of β-CD or different nanosponges was added into it. The vials were placed on a 176 
mechanical shaker for 24 hours at room temperature. Later, the suspension was centrifuged at 177 
6000 rpm for 15 minutes and the supernatant was collected. All the samples were filtered using a 178 
0.45 µm syringe filter and analyzed on HPLC as mentioned in section 2.2.6.  179 
2.2.4 Preparation of KYNA loaded nanosponge  180 
KYNA loaded nanosponge was prepared by the freeze-drying method as established earlier 181 
(Zidan, Ibrahim, Afouna, & Ibrahim, 2018). An aqueous suspension of individual nanosponges 182 
(β-CDNS1 to β-CDNS3) was prepared (10 mg/ml) and the required quantity of KYNA was 183 
added into it at different weight ratio of 1:3, 1:4 and 1:5 (w/w), respectively. The suspension was 184 
sonicated for 10 minutes and stirred for 24 hours at room temperature. Later, the suspension was 185 
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centrifuged at 6000 rpm for 15 minutes to remove the non-complexed drug. The supernatant was 186 
collected, 5 % trehalose (% w/v) was added as a cryo-protectant and freeze-dried.  187 
The freeze-dried formulations of KYNA were abbreviated as KYNA-β-CDNS1, KYNA-β-188 
CDNS2, and KYNA-β-CDNS3, respectively.  189 
2.2.5 Preparation of a physical mixture  190 
Physical mixtures were also prepared by mixing drug (2.5 mg) with different nanosponges (10 191 
mg) by trituration in a mortar for 30 min at room temperature. The physical mixture formulations 192 
were abbreviated as PM1, PM2, and PM3, respectively.  193 
2.2.6 Quantitative determination of KYNA by HPLC  194 
The quantitative determination of KYNA was performed by an HPLC system (PerkinElmer, 195 
Waltham, USA) equipped with a UV detector (Flexar UV/Vis LC spectrophotometer) using a 196 
phenomenex C18 analytical column (4.6 mm x 250 mm, 5 µm). The mobile phase consisted of a 197 
mixture of 0.14 % (v/v) TFA (trifluoroacetic acid) in water-acetonitrile (90:10 v/v), filtered and 198 
ultrasonically degassed prior to use. The mobile phase was pumped through the column at a flow 199 
rate of 1 ml/min and the samples (20 µl) were analyzed at 330 nm using a UV detector (Lesniak 200 
et al., 2013) 201 
2.2.7 Determination of KYNA loading efficiency  202 
The KYNA loaded NS was taken into a vial containing 1 ml of DMSO-water mixture (50:50) 203 
and sonicated for 1 hour. Later, it was filtered and suitably diluted with mobile phase and 204 
analyzed on HPLC.  205 
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2.2.8 Determination of particle size, polydispersity index, and zeta potential  206 
The particle size and polydispersity index were studied by DLS using a Malvern Zetasizer 207 
Nano instrument at a fixed scattering angle of 90ᵒ. All the samples were suitably diluted by milli-208 
Q water and analyzed at 25 ℃. Zeta potential of all the samples was calcu ated on the same 209 
instrument placing an additional electrode. All the measurements were performed in triplicate.  210 
2.2.9 Differential Scanning Calorimetry (DSC) 211 
Thermal properties of KYNA, blank NS, physical mixture, and KYNA loaded NS were 212 
evaluated using a TA instruments Q200 DSC (New Castle, DE, USA). The empty aluminum pan 213 
was used as a reference standard and samples (2-3 mg) were scanned from 30 to 300 ℃ at the 214 
scanning rate of 10 ℃/min under a nitrogen purge.  215 
2.2.10 Fourier transform infrared spectroscopy (FTIR) 216 
The FTIR spectra of KYNA, blank NS, physical mixture, and KYNA loaded NS were 217 
recorded on PerkinElmer 100 FTIR using an attenuated total reflectance (ATR) accessory. All 218 
the samples were scanned from 4000-650 cm-1 at a resolution of 4 cm-1 and 8 scans/spectrum. 219 
The % crosslinking of nanosponges was also determined with some modifications as reported 220 
earlier (Coma, Sebti, Pardon, Pichavant, & Deschamps, 2003; Ghorpade, Yadav, & Dias, 2016). 221 
The detailed information of method and sample preparation is mentioned in the supplementary 222 
information.  223 
2.2.11 X-ray powder diffraction studies (PXRD) 224 
The XRD spectra of KYNA, blank NS and KYNA loaded NS were recorded using Malvern 225 
Panalytical X’Pert diffractometer using Cu Kα1 as a source of radiation. Data was collected over 226 
an angular range from 5 to 45 ᵒ2θ at a step size of 0.017 ᵒ2θ and a time per step of 100.33 s. 227 
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2.2.12 Morphology evaluation of nanosponge and drug complex  228 
The surface morphologies of blank NS, and KYNA loaded NS were evaluated on Field 229 
Emission Scanning Electron Microscope (FE-SEM; ZIESS Supra 40). Approximately, 3-4 drops 230 
of NS suspension were placed on a copper stub and air dried later, sputter coated with gold. 231 
Samples were analyzed at 3 kV accelerating voltage at a working distance of 10 mm.  232 
2.2.13 The in-vitro drug release profile  233 
The accurate weight amount of KYNA loaded NS (20 mg) was dispersed in 3 ml of phosphate 234 
buffer pH 7.4 and sealed into a dialysis bag (12,400 MWCO). It was submerged into 30 ml of 235 
phosphate buffer pH 7.4 at 37 ± 0.5 ℃ with a rotation speed of 50 rpm. The aliquots (1 ml) were 236 
withdrawn at different time intervals and replaced with the same amount of fresh phosphate 237 
buffer to maintain sink condition. Later, all the samples were analyzed on HPLC. 238 
2.2.14 Evaluation of antioxidant activity  239 
2.2.14.1  TBA Assay 240 
This assay is based on the oxidative decomposition of polyunsaturated fatty acid in acidic 241 
medium to generate malondialdehyde (MDA), which reacts with TBA to form TBA-MDA 242 
adduct (Yen, Chang, & Su, 2003). Two different concentrations (50 µM and 100 µM) of KYNA 243 
(1 mg/ml stock solution in N-methyl pyrrolidone) and KYNA loaded NS in phosphate buffer pH 244 
7.4 were prepared. 0.1 ml of linoleic acid (1 % w/v) was taken in a test tube, 0.2 ml of sodium 245 
dodecyl sulfate (SDS) (4 % w/v), 1.5 ml of phosphoric acid (1.0 % v/v), 1.0 ml of TBA (0.6 % 246 
w/v), 0.1 ml of water and 0.1 ml of KYNA solution or KYNA loaded NS was added into it. The 247 
mixture was heated at 100 ℃ for 45 minutes later it was cooled down on an ice bath and mixed 248 
with 1-butanol (4 ml) to extract TBA-MDA adduct. Samples were analyzed by UV-Visible 249 
spectrophotometer (Lambda 25, PerkinElmer, Waltham, USA) at 535 nm and MDA 250 
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concentration was determined from a calibration curve of a MDA precursor 1,1,3,3-251 
tetraethoxypropane (TRP), which was recorded under the same experimental conditions. The 252 
antioxidant activity of KYNA was evaluated by determining the reduction in the MDA 253 
generation.  254 
The effect of potent oxidant (KMnO4) on lipid peroxidation and its inhibition by KYNA or  255 
KYNA loaded NS was also studied using additional 0.1 ml of KMnO4 (1 mM) solution 256 
following the procedure as mentioned above. 257 
2.2.14.2 DPPH scavenging activity 258 
The DPPH scavenging activity of KYNA loaded NS was studied and compared with the 259 
KYNA solution as demonstrated earlier (Colombo, Figueiró, Dias, Amanda de Fraga Teixeira, 260 
Battastini, & Koester, 2018). Different concentrations of KYNA and KYNA loaded NS (10-100 261 
µM) were prepared. An ethanolic solution of DPPH (0.004 % w/v) was prepared, of which 0.5 262 
ml were mixed with either KYNA solution or KYNA loaded NS (2 ml). Later, the mixture was 263 
incubated for 60 minutes and analyzed by UV-visible spectrophotometer at 525 nm. Ethanol (0.5 264 
ml) was used as control (without drug) and results were compared with L-ascorbic acid as a 265 
positive standard. The percentage of DPPH scavenging activity was calculated using the 266 
following equation.  267 
DPPH Inhibition (%) =
 Absorbance of control − Absorbance of sample
Absorbance of control
 x 100 
2.2.14.3 H2O2 Scavenging activity  268 
The H2O2 scavenging activity of KYNA and KYNA loaded NS was evaluated as reported 269 
earlier (Ebadollahinatanzi & Moghadasi, 2016). Briefly, a series of concentrations of KYNA and 270 
KYNA loaded NS (10-100 µM) were prepared. The reaction was carried out between 0.5 ml of 271 
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KI (1M), 0.5 ml of TCA (0.1% w/v), 0.5 ml of phosphate buffer pH 7.4, 0.5 ml of H2O2 (10 mM) 272 
and KYNA or KYNA loaded NS (0.5 ml) at room temperature for 10 minutes. The phosphate 273 
buffer pH 7.4 (0.5 ml) was added instead of drug solution as a control. The absorbance was 274 
recorded by UV-Vis spectrophotometer at 350 nm.  275 
The following equation was used to calculate the percentage of H2O2 scavenging activity.  276 
H₂O₂ Scavenging Activity (%) =
Absorbance of control − Absorbance of sample 
Absorbance of control 
 x 100 
2.2.15 Cell viability studies  277 
SHSY-5Y human neuroblastoma cell lines were purchased from ATCC (Manassas, VA, 278 
USA). The cells were cultured as a monolayer in RPMI 1640 medium accompanied with 10 % 279 
fetal calf serum, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37 ℃ and maintained under 280 
5 % CO2 atmosphere. The cell viability of KYNA, KYNA loaded NS and blank NS was 281 
evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 282 
SHSY-5Y cell lines were seeded into a 96-well plate and incubated for 24 hours at 37 ℃ in a 5 283 
% CO2 humidified atmosphere. The cells were incubated with increasing concentrations of 284 
KYNA or KYNA loaded NS (1-100 µM) for 24 hours. The Blank NS was also dispersed in 0.9 285 
% NaCl saline solution and treated with the cells as mentioned above. After 24 hours, cell 286 
viability was evaluated using MTT by recording the absorbance at 570 nm according to the 287 
manufacturer’s protocol. The cells treated with culture medium alone considered as a control and 288 
the reading obtained from treated cell were expressed as % cell viability. 289 
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2.2.16 Stability study of KYNA loaded NS  290 
The in vitro stability of blank NS and KYNA loaded NS in 0.9 % NaCl saline solution was 291 
evaluated. All the samples were incubated at 4 ℃ for a period of 1 week. The average diameter 292 
and zeta potential of blank NS and KYNA loaded NS were studied at different time intervals.  293 
2.2.17 Statistical analysis  294 
The experiments are expressed as mean ± standard deviation (SD). The significance of the 295 
difference was evaluated by one-way ANOVA followed by Bonferroni correction using 296 
GraphPad Prism 5 software (GraphPad Software, USA). A p-value ˂ 0.05 was considered as 297 
statistically significant.  298 
3. Results and discussion  299 
3.1 Physicochemical Characterization of NS and KYNA loaded NS  300 
The presence of a large number of hydroxyl groups of β-CD makes it a suitable candidate for 301 
the crosslinking reaction. The nanosponges were synthesized by the formation of a carbonate 302 
bond between CDI and the hydroxyl groups of β-CD. The swelling degree of the prepared NS 303 
was determined. A moderate swelling degree was achieved with β-CDNS2 (251 %), compared to 304 
β-CDNS1 (200 %) and β-CDNS3 (168 %). However, no evident trend was observed. 305 









Figure 1. 308 
The solubilization of KYNA alone and in the presence of β-CD or different nanosponges was 309 
also studied as presented in Fig. 1(B). The solubility of KYNA with different nanosponges was 310 
significantly higher compared to both free KYNA (16.4 µg/ml) and KYNA with β-CD (28.6 311 
µg/ml). The solubility of KYNA increased to 5.3 folds with β-CDNS1 and 6.77 folds with β-312 
CDNS2. However, KYNA solubility further decreased with β-CDNS3 (5.65 folds) because of 313 
the higher cross-linker concentration that formed more complex nanochannel which hindered the 314 
drug encapsulation (Torne et al., 2013). The maximum solubilization of KYNA was achieved 315 
with β-CDNS2 (Fig. S1; Supporting Information), thus β-CDNS2 was selected for drug loading 316 
studies. 317 
Later, drug loading study was carried by taking different KYNA to β-CDNS2 concentrations 318 
in weight ratios of 1:3, 1:4 and 1:5 w/w. The maximum drug loading of 19.06 % was achieved 319 
with 1:4 w/w compared to 12.7 % (1:3 w/w) and 19.19 % (1:5 w/w), respectively. A significant 320 
difference in drug loading was observed in between 1:3 w/w and 1:4 w/w. However, no further 321 
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change in drug loading was seen in between 1:4 w/w and 1:5 w/w might be due to saturation 322 
solubility of KYNA (Zidan et al., 2018).  323 
Depending on the drug loading studies KYNA loaded NS (1:4 w/w) subjected to further 324 
studies. The average particles size and zeta potential of blank nanosponge and KYNA loaded NS 325 
were determined as shown in Table 2.  326 
Table 2. 327 
Properties 
Blank NS  
(β-CDNS2) 
KYNA loaded NS 
(KYNA-β-CDNS2) 
Particle Size (nm) 224.43 ± 3.72 255.8 ± 7.88 
PDI 0.35 ± 0.040 0.32 ± 0.043 
Zeta Potential (mV) -26.3 ± 1.91 -23 ± 0.945 
Encapsulation Efficiency (%) - 95.31 % 
 328 
The DSC thermogram of KYNA showed an endothermic peak at 277.15 ℃ that 329 
corresponds to its melting temperature as shown in Fig. 2(I). The nanosponges are stable thus do 330 
not undergo any thermal transition and physical mixture showed endothermic transition similar 331 
to KYNA with lesser intensity because of the possible dilution with NS. It is reported that 332 
encapsulation of drug molecules within the NS leads to the formation of an amorphous system 333 
(Ansari et al., 2011). A similar pattern was observed with KYNA loaded NS which did not 334 
produce any significant endothermic melting because of possible amorphization of KYNA, thus 335 
confirming the encapsulation of KYNA within the nanosponges.  336 
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Fig. 2(II) shows the FTIR spectra of KYNA, blank NS, physical mixture and KYNA 337 
loaded NS. The FTIR spectrum of KYNA showed strong characteristic peaks at 3095 cm-1 (-N-H 338 
stretching), 2940 cm-1 (-C-H stretching), 1660 cm-1 (-C=C stretching), 1362 cm-1 (-OH bending), 339 
1121 cm-1 (-C-O  stretching). The occurrence of carbonate bond peak at 1739 cm-1 in the FTIR 340 















Figure 2. 343 
 344 
Moreover, FTIR spectrum of the physical mixture showed the superposition of FTIR 345 
peaks of both KYNA and NS without any shift or suppression, confirming no interaction or 346 
encapsulation of KYNA with NS. However, the FTIR spectrum of KYNA loaded NS showed the 347 
disappearance of peaks at 3095 cm-1 (-N-H stretching), and a significant shift in the absorption 348 
band at 3318 cm-1 (-OH stretching), and 1743 cm-1 (-C=O stretching) indicating the interaction of 349 
KYNA with NS because of the possible encapsulation of drug. The extent of crosslinking of 350 
nanosponges was determined from the ratio of the two peaks (I1774/I2929) which corresponds to 351 
the carbonyl group stretching of the crosslinker and C-H stretching of β-CD, respectively. It was 352 
observed that the high ratio of I1774/I2929 was obtained by increasing the crosslinker concentration 353 
due to increment in the I1774 band of the carbonyl group (Table S1; Supporting Information). It 354 
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suggested that higher crosslinker concentration leads to higher crosslinking of the nanosponges. 355 
β-CDNS1 showed lowest crosslinking of 59.49 % compared to β-CDNS2 (79.42 %) and β-356 
CDNS3 (83.7 %) (Fig. S2-S4; Supporting Information). The % crosslinking values were similar 357 
to those reported earlier for other cyclodextrins nanosponges (Gholibegloo et al., 2019; P. Singh 358 
et al., 2018).  359 
The PXRD pattern of KYNA showed sharp and intense peaks at 8.01, 9.90, 12.62, 16.07, 360 
24.79, 28.22, 31.68, and 39.89 2θ values that indicates crystalline behavior of KYNA as shown 361 
in Fig. 2(III). The PXRD of blank NS did not show any sharp peaks in agreement with its 362 
amorphous nature. The disappearance of characteristic peaks of KYNA in KYNA loaded NSs 363 
indicate a loss in the crystallinity and consequent amorphization of KYNA because of the 364 
encapsulation of KYNA inside the NSs. Such evidence suggested the formation of an inclusion 365 
complex (Darandale & Vavia, 2013; Dora et al., 2016). However, in case of physical mixture 366 
characteristic peaks of KYNA were clearly visible with lesser intensity, suggesting no change in 367 
the property of KYNA, which remained in the crystalline form. The PXRD pattern of β-CD was 368 
also determined and the presence of sharp peaks clearly indicated crystalline structure of it in 369 







Figure 3. 371 
Fig. 2(IV) shows the FE-SEM images of blank NS and KYNA loaded NS in which both 372 
showed small spherical shape particles of diameter less than 200 nm with appropriate size 373 
distribution. Furthermore, fig. 3 presents the N2 adsorption-desorption isotherm and pore 374 
distribution curve of blank NS. As shown in fig. 3(A), a type IV isotherm with hysteresis loop 375 
was observed for NS. The presence of hysteresis loop could be attributed to the mesoporous 376 
structure of the NS. Moreover, fig. 3(B) displayed the pore distribution of NS which further 377 
suggest the mesoporosity of NS as the pore diameter was 50-70 Å (5-7 nm). The surface area of 378 
blank NS was less than 1 m2/g. It is also reported that the surface area and porosity can be 379 
tailored depending upon the cross-linker concentration. The results obtained were in agreement 380 
with those previously reported in the literature for other cyclodextrin nanosponges (Gholibegloo 381 
et al., 2019; Pushpalatha, Selvamuthukumar, & Kilimozhi, 2018). Moreover, BET analysis of 382 
KYNA loaded NS showed a type IV isotherm with hysteresis loop similar to blank NS. 383 
However, porosity of KYNA loaded NS (35-45 Å) was reduced which might be due to 384 
encapsulation of KYNA within the NSs (Fig. S6; Supporting Information). 385 
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The in-vitro release profile of KYNA loaded NS was studied in phosphate buffer pH 7.4 386 
(Fig. 4). A slow and uniform drug release profile of KYNA was observed without any initial 387 
burst effect. The slower drug release profile can be attributed to the presence of KYNA inside 388 
the cavities of nanosponges. Moreover, the absence of an initial burst release further confirmed 389 
that the drug was not partially encapsulated or adsorbed on the surface of nanosponges. The 390 
different drug release kinetics models (such as zero order, first order, Higuchi-Connors, Hixen-391 
Crowell, and Korsmeyer-Peppas) were applied and the release profile of KYNA was best fitted 392 
to Higuchi-Connors release kinetic model (R2 = 0.995) indicating that drug release was carried 393 
out by diffusion from the nanosponges (Machín, Isasi, & Vélaz, 2012; Zainuddin, Zaheer, 394 
Sangshetti, & Momin, 2017). 395 
Plain KYNA was found to be dissolved very rapidly and uncontrolled release was 396 
observed. Plain KYNA showed that equilibrium was achieved within a few minutes during in-397 
vitro release profile. Moreover, rapid drug release is associated with dose related toxic effects. 398 
Therefore, controlled drug delivery, which can be achieved by encapsulation of drug within NSs, 399 





Figure 4. 403 
3.2 Evaluation of antioxidant activity 404 
Phenolic compounds exhibit antioxidant activity because of their ability to react with free 405 
radicals at a faster rate. The antioxidant activity of KYNA might be because of the presence of 406 
an aromatic hydroxyl group that readily provides protons for the reaction with free radicals. 407 
Moreover, the presence of nitrogen in the aromatic ring or carboxylic acid acting as an electron 408 
withdrawing group helps to stabilize the free radical produced by donation of the proton 409 
(Zhuravlev, Zakharov, Shchegolev, & Savvateeva-Popova, 2016).   410 
The generation of MDA because of the degradation of fatty acid is a common indicator 411 
for determining the degree of lipid peroxidation. MDA reacts with TBA to produce a pink TBA-412 
MDA adduct. The production of MDA is shown in fig. 5 and it was observed that KYNA loaded 413 
NS produced a lesser amount of MDA (P<0.001) compared to free KYNA. A decreased 414 
production of MDA might be because of the inhibiting and scavenging effect of KYNA on ROS 415 




Figure 5. 418 
The effect of KYNA on MDA generation in the presence of the strong oxidizing agent 419 
(i.e. KMnO4) was also studied and it was observed that oxidizing agent generated a large amount 420 
of MDA because of the rapid and higher oxidation of fatty acid. However, free KYNA and 421 
KYNA loaded NS significantly decreased the production of MDA even in the presence of the 422 
oxidizing agent, demonstrating its antioxidant potential. Moreover, KYNA loaded NS was more 423 
effective compared to free KYNA, this might be because of the higher solubilization of KYNA 424 
with NS. 425 
The DPPH assay is based on the reduction of its absorbance at 517 nm because of the 426 
acceptance of proton. Fig. 6(A) illustrates the DPPH inhibition effect of KYNA at different 427 
concentrations. It was observed that the DPPH inhibition effect of KYNA was increased in a 428 
dose-dependent manner. Moreover, the KYNA loaded NS showed a higher reduction (P<0.001) 429 








Figure 6. 432 
The higher antioxidant activity of KYNA loaded NS can be attributed to enhanced 433 
solubilization of KYNA with nanosponge thus readily provided protons to DPPH. The results 434 
obtained are in agreement with those reported in the literature. Sundararajan et al. demonstrated 435 
that chrysin loaded NS produced more than 2 fold DPPH inhibition compared to free chrysin. 436 
(Sundararajan, Thomas, Venkadeswaran, Jeganathan, & Geraldine, 2017).  437 
Moreover, the antioxidant property of KYNA was further evaluated by hydrogen 438 
peroxide scavenging activity. The hydrogen peroxide is a very reactive compound that generates 439 
hydroxyl radicals. The hydroxyl radicals are the most common reactive oxygen species (ROS) 440 
that can cause cell death because of the oxidative degradation of biomolecules such as DNA, 441 
RNA, and proteins. Thus, to demonstrate the antioxidant potential of KYNA, its H2O2 442 
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scavenging effect was studied. Fig. 6(B), shows the hydrogen peroxide scavenging effect of 443 
KYNA, KYNA loaded NS and L-ascorbic acid. 444 
All the samples showed concentration-dependent H2O2 inhibition. The KYNA loaded NS 445 
showed better H2O2 inhibition compared to free KYNA ranging from 17 % to 78 % at the tested 446 
concentration range. It might be possible that KYNA loaded NS reacts rapidly with peroxide 447 
intermediates to exhibit better H2O2 inhibition due to high KYNA solubilization. It is also 448 
evident that the standard solution of L-ascorbic acid is more effective compared to KYNA and 449 
KYNA loaded NS. The above-mentioned tests were also carried out on blank NS to determine 450 
the antioxidant activity of NS alone. However, no significant results were obtained as they do not 451 
exhibit antioxidant activity (Fig. S7; Supporting Information). 452 
The results observed are in agreement with those reported in the literature. Lugo-Huitrón 453 
et al. demonstrated the scavenging capacity of KYNA compared to known reference compounds 454 
and suggested that KYNA acts as a potent inhibitor of ROS (Lugo-Huitrón et al., 2011). In 455 
another study, Genestet and co-workers demonstrated the superoxide scavenging activity of 456 
KYNA. They demonstrated that KYNA showed better antioxidant activity compared to other 457 
tryptophan metabolites (Genestet et al., 2014).   458 
3.3 Cell Viability 459 
The biocompatibility of SHSY-5Y cell lines with blank NS was determined using a MTT 460 
assay at the concentration of 5-500 µg/ml indicated that blank nanosponge does not produce any 461 
significant toxic effect even at higher concentration thus confirming the safety of our nanocarrier 462 
(fig. 7). The minimum cell viability was 89 % at the concentration of 500 µg/ml after 24 hours. 463 
The results obtained are in agreement with previously reported data indicating that NS does not 464 
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produce any significant toxicity on different cell lines (Gholibegloo et al., 2019; Mognetti et al., 465 






Figure 7. 467 
The effect of KYNA and KYNA loaded NS was also evaluated on the survival of SHSY-5Y 468 
cell lines. Both KYNA and KYNA loaded NS do not produce any significant toxic effects on cell 469 
lines at the concentration of 1-100 µM. Furthermore, 90 % or more cell survival was observed at 470 
all the tested concentrations with KYNA and KYNA loaded NS. Klein et al. earlier demonstrated 471 
the effect of KYNA and its derivatives on the survival of SHSY-5Y cell lines which suggested 472 
that KYNA promotes higher cell survival of SHSY-5Y cell lines compared to the structurally 473 
modified derivative of KYNA (Klein et al., 2013). Researchers have also tried to prepare water-474 
soluble salts of KYNA to improve the performance in the neurological applications. However, 475 
selectivity and stability of salts of KYNA are always the major concerns. Dalpiaz et al., prepared 476 
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6-bromo-ascorbic acid derivative of KYNA and reported that it showed the affinity to the 477 
vitamin C transporters, however, does not show any permeation because of the enzymatic 478 
hydrolysis (Dalpiaz et al., 2005). In another study Baron et al., prepared a KYNA analog and 479 
showed that higher concentration of KYNA analog was needed to produce glutamate inhibition 480 
compared to native KYNA (Baron et al., 1992). It suggested that native KYNA shows better 481 
neurological effects compared to its derivatives, therefore, NSs can be employed as a delivery 482 
vehicle for KYNA without any undesirable effects.  483 
3.4 Stability study  484 
The stability of blank NS and KYNA loaded NS was evaluated at 4 ℃ for a week. The 485 
particle size and zeta potential were studied to assess the stability of the blank NS and KYNA 486 
loaded NS. The change in the particle size and zeta potential is demonstrated in fig. 8(A) and 487 





Figure 8. 489 
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It was observed that the particle size of blank NS was increased from 224.4 nm to 289.7 490 
nm compared to KYNA loaded NS that showed a slight increase from 255.8 nm to 298.8 nm. 491 
Moreover, the zeta potential was also observed in the desired range without any significant 492 
change. Argenziano et al. earlier demonstrated that particle size of drug loaded NSs do not show 493 
any significant increment on storage for 24 hours (Argenziano et al., 2018). However, another 494 
study revealed that other hyper cross-linked polymer of cyclodextrin showed more than 2-fold 495 
increment in the particles size on storage within a week (Gref et al., 2006). On the basis of the 496 
above results, it is clear that these NSs provide better protection from aggregation and remained 497 
stable for the period of a week at 4 ℃. 498 
4. Conclusion  499 
In the present study, we demonstrated the synthesis of KYNA loaded NS and it was 500 
observed that high solubilization and drug loading of KYNA was achieved with β-CDNS2. The 501 
higher solubilization of KYNA was obtained because of the encapsulation of KYNA in the 502 
cyclodextrin cavities and porous matrix of NS. The KYNA loaded NS was characterized by 503 
FTIR, DSC, and PXRD which confirmed the formation of an inclusion complex of KYNA with 504 
NS. The antioxidant potential of KYNA and KYNA loaded NS was studied which further 505 
confirmed that KYNA loaded NS shows better antioxidant activity compared to free KYNA 506 
which can be attributed to the change in the physiochemical property and higher solubilization of 507 
KYNA with NS. The cytotoxicity of KYNA and KYNA loaded NS was also evaluated on 508 
SHSY-5Y cell lines which demonstrated that KYNA alone and in the presence of NS does not 509 
produce any significant toxic effect. Moreover, nanosponge alone was found to be non-toxic. 510 
Thus, the above study demonstrated that cyclodextrin nanosponge acts as a promising carrier for 511 
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the delivery of KYNA and can possibly be employed in biological systems for its antioxidant 512 
potential.  513 
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Figure Captions 520 
Fig 1. (A) Structure of KYNA. (B) Solubilization efficiency of KYNA, β-CD and different 521 
nanosponges. All the values present data in triplicate (mean ± SD); * indicates P < 0.05 and *** 522 
indicates P < 0.0001. 523 
Fig 2. (I) DSC thermograms of KYNA, physical mixture, blank NS and KYNA loaded NS. (II) 524 
FTIR spectra of KYNA, physical mixture, blank NS and KYNA loaded NS. (III) PXRD pattern 525 
of KYNA, physical mixture, blank NS and KYNA loaded NS. (IV) FE-SEM images of blank NS 526 
(A), and KYNA loaded NS (B) (scale bar = 200 nm). 527 
Fig 3. N2 absorption-desorption (A) and porosity curve of β-CDNS2 (B). 528 
Fig 4. In-vitro release kinetics of KYNA from NS. 529 
Fig 5. The inhibition of lipid peroxidation by KYNA loaded NS in the absence of oxidizing 530 
agent (left) and in the presence of the oxidizing agent (right). Statistical significance *** 531 
indicates P < 0.0001. 532 
Fig 6. The Percentage DPPH inhibition (A) and H2O2 scavenging activity (B) by KYNA, KYNA 533 
loaded NS and L-ascorbic acid. 534 
Fig 7. The evaluation of in-vitro cytotoxicity study of KYNA and KYNA loaded NS (A) and 535 
blank NS (B) on SHSY-5Y cell lines after 24 hours. 536 
Fig 8. The in-vitro stability study of blank NS and KYNA loaded NS to determine particles size 537 
(A) and zeta potential (B). All the values present in terms of mean ± SD (n = 3). 538 
  539 
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Table Captions 540 
Table 1. Quantities of chemicals used for preparing nanosponges. 541 
Table 2. Physicochemical characteristics of Blank and KYNA loaded NS. 542 
 543 
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